Integrated Wealth Concepts LLC Acquires 2,361 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Integrated Wealth Concepts increased its Thermo Fisher Scientific stake by 38.3% in the second quarter, purchasing 2,361 shares and bringing its holdings to 8,524 shares worth approximately $4.27 million. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported quarterly earnings of $6.03 per share on $11.99 billion in revenue, exceeding analyst estimates, while revenue grew 10.5% year over year. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• TMO shares opened at $610.97, near the analyst consensus price target of $624.64, with a “Moderate Buy” consensus rating. The company declared a quarterly dividend of $0.47 per share, while insiders have sold 73,768 shares worth roughly $44.1 million over the past 90 days.

Integrated Wealth Concepts LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 38.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,524 shares of the medical research company's stock after purchasing an additional 2,361 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Thermo Fisher Scientific were worth $4,274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of TMO. High Note Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after acquiring an additional 29 shares during the period. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Kilter Group LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $25,000. Legacy Wealth Managment LLC ID raised its stake in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after buying an additional 22 shares during the last quarter. Finally, Birchwood Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $610.97 on Friday. The stock has a 50-day simple moving average of $580.40 and a two-hundred day simple moving average of $518.55. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The firm has a market capitalization of $225.90 billion, a PE ratio of 32.87, a P/E/G ratio of 2.55 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business's quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Insider Activity

In other news, EVP Michael Shafer sold 25,500 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This trade represents a 54.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently commented on TMO shares. CLSA started coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They issued an "outperform" rating and a C$748.00 price objective for the company. KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Royal Bank Of Canada upped their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. Sanford C. Bernstein began coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective on the stock. Finally, BMO Capital Markets lowered shares of Thermo Fisher Scientific to a "market perform" rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $624.64.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.